Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 1, 2005, Pages 68-75

  Tsai, Jung Fa ^a   Jeng, J E ^a   Chuang, L Y ^a   You, H L ^a   Wang, L Y ^a   Hsieh, M Y ^a   Chen, S C ^a   Chuang, W L ^a   Lin, Z Y ^a   Yu, M L ^a   Dai, C Y ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

fetoprotein; Insulin like growth factor II; Liver cirrhosis; Receiver operating characteristic curve; Small hepatocellular carcinoma; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; SOMATOMEDIN B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; IGF 2 GENE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 19944433542     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410009311     Document Type: Article

References (36)

1. Colombo M. Malignant neoplasms of the liver. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiffs disease of the liver. Philadelphia: Lippincott Williams & Wilkins; 2003. pp 1377-403.
2. Sherlock S, Dooley J. Malignant liver tumors. In: Disease of the liver and biliary system, 11th ed. Oxford: Blackwell Publishing Co; 2002. pp 537-62.
3. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi GC, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.
4. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
5. Bruix J, Sherman M, Llovert JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC: clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Eur Assoc Study Liver J Hepatol 2001;35:421-30.
6. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumor markers of hepatocellular carcinoma. Br J Cancer 1995;72:442-6.
7. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Clinical evaluation of urinary transforming growth factor-β1 and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Br J Cancer 1997;75:1460-6.
8. Tsai JF, Chuang LY, Jeng JE, Yang ML, Chang WY, Hsieh MY, et al. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine 1997;76:213-26.
9. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, et al. Serum α-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984;86:1404-9.
10. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986;90:289-98.
11. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.
12. Shinagawa T, Ohto M, Kimura K, Tsunetomi S, Morita M, Saisho H, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. A study in 51 patients. Gastroenterology 1984;86:495-502.
13. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, et al. Transforming growth factor-beta 1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002;94:78-80.
14. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
15. Fan ZR, Yang DH, Cui J, Qin HR, Huang CC. Expression of insulin-like growth factor II and its receptor in hepatocellular carcinogenesis. World J Gastroenterol 2001;7:285-8.
16. Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003;9:267-70.
17. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988;48:6844-9.
18. Song BC, Chung YH, Kim JA, Lee HC, Yoon HK, Sung KB, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellularcarcinoma: a prospective study. Cancer 2001;91:2386-93.
19. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997;76:968-74.
20. Tsai JF, Chang WY, Jeng JE, Wang LY, Hsieh MY, Chen SC, et al. Hepatitis C virus infection as a risk factor for nonalcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296-300.
21. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994;14:98-102.
22. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R. Transection of the esophagus for bleeding esohphageal varices. Br J Surg 1973;60:646-9.
23. Leroith D, Clemons D, Nissley P, Rechler MM. Insulin-like growth factors in health and disease. Ann Intern Med 1992;116:854-62.
24. Bernstein LH, Leukhardt-Falrfield CJ, Pleban W, Rudolph R. Usefulness of data on albumin and prealbumin concentrations in determining effectiveness of nutritional support. Clin Chem 1989;35:271-4.
25. Sox HC, Blatt MA, Higgins MC, Marton K. Medical decision making. London: Butterworth & Co. Ltd; 1989. pp 67-146
26. Zweig MH, Campbll G. Receiver-operating chracteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
27. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
28. Tsai JF, Tsai JH, Chang WY. Relationship of serum α-feto protein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Gastroenterol Jpn 1990;25:388-93.
29. Tsai JF, Tsai JH, Chang WY, Ton TC. Elevation of circulating immune complexes and its relationship to α-fetoprotein levels in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Cancer Invest 1991;9:137-43.
30. Chuang LY, Hung WC, Yang ML, Chang CC, Tsai JF. Urinary epidermal growth factor receptor-binding growth factors in patients with cancers of the digestive tract. Clin Biochem 1994;27:485-9.
31. Edis C, Kahler C, Klotz W, Herold M, Feichtinger H, Konigsreiner A, et al. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant Proc 1998;30:780-1.
32. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002;49:235-8.
33. Maussier ML, Valenza V, Schinco G, Galli G. AFP, CEA, CA19-9 and TPA in hepatocellular carcinoma. Int J Biol Markers 1990;5:121-6.
34. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.
35. Kaneko S, Unoura M, Kobayashi K. Early detection of hepatocellular carcinoma. In: Okud K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997. pp 393-406.
36. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001;54:138-44.